To Be Discontinued Oral Suspension Cardiovascular
Chlorothiazide Oral Suspensi · 213 days since initial FDA posting
Brand: DIURIL
FDA lists Chlorothiazide Oral Suspensi as To Be Discontinued (Salix Pharmaceuticals, a division of Bausch Health US, LLC).
No availability text on this FDA row.
Chlorothiazide Oral Suspension: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Chlorothiazide Oral Suspension
- Manufacturer
- Salix Pharmaceuticals, a division of Bausch Health US, LLC
- Dosage Form
- Oral Suspension
- Presentation
- Diuril, Oral Suspension, 250 mg/5mL (NDC 65649-311-12)
- Package NDC
- 65649-311-12
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Feb 10, 2026
- Last Updated
- Feb 10, 2026
- Therapeutic Category
- Cardiovascular
Row fields from the FDA Drug Shortages database via openFDA.